MBX Biosciences opened lower at $57.22, compared with its previous close of $57.72. In the last trading session, the stock traded between $54.30 and $57.82. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 3 years ago in MBX Biosciences is now worth
$ 230.36
Giving a profit of
$ 130.36 (130.36%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 5 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-3.24 (-5.61%)
Day High
$57.82
Day Low
$54.30
Day Open
$57.22
Prev Close
$57.72
Volume
2,60,948
1W Return
3.73%
1M Return
4.76%
3M Return
-17.44%
6M Return
35.93%
1Y Return
118.71%
Fundamentals
Market Cap ($ Mn)
2,705
PE Ratio
-
PB Ratio
7.38
PEG Ratio
-
ROE
-29.60%
ROCE
-33.34%
EPS (TTM)
-
Investment Returns
1 Week
3.73%
1 Month
4.76%
3 Months
-17.44%
6 Months
35.93%
9 Months
55.66%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
0.0
Sep 26
Updates
10Nov
MBX Biosciences Q3 EPS $(1.29) misses estimate amid $62.4M net loss
MBX Biosciences reported Q3 EPS of $(1.29), missing the analyst estimate of $(0.84). Net loss widened to $62.4 million in Q3 2026, up from $21.6 million in Q3 2025. R&D expenses rose to $32.0 million, driven by Phase 3 canvuparatide trial start-up costs. G&A expenses surged to $34.3 million, including a $20.8 million non-recurring stock-based compensation charge. Cash and investments stood at $481.6 million, expected to fund operations into 2029.
MBX Biosciences delivered a disappointing second-quarter report, with EPS losses of $(0.78) missing the $(0.63) estimate by 23.81%. The results reflect a 34.48% year-over-year increase in losses compared to $(0.58) in the prior year, indicating deteriorating profitability trends that exceed market expectations.
3mo ago
14Jul
MBX Biosciences appoints Steve Hoerter as Chairman and CEO
MBX Biosciences has appointed Steve Hoerter as Chairman and CEO, effective immediately, succeeding Kent Hawryluk. John Smither has been appointed as the permanent Chief Financial Officer after serving as Interim CFO. The company is targeting key milestones in the second half of 2026, including Phase 3 trial initiation.
4mo ago
12Jun
MBX Biosciences highlights sustained calcium control in rare disease
MBX Biosciences Inc. announced full results from the 12-week Avail Phase 2 trial and new one-year data from an ongoing open-label extension study of once-weekly canvuparatide in adults with chronic hypoparathyroidism. The data demonstrated a responder rate of 57% at one year, comparable to the 63% rate observed at 12 weeks, with sustained calcium normalization and improved kidney function. The company remains on track to initiate the Phase 3 pivotal trial in Q3 2026.
